1001646-83-8

Upstream product

• 100564-78-1 (2R)-(tert-butoxycarbonylamino)-4-phenylbutanoic acid 
• 77-78-1 dimethyl sulfate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1404461-83-1 N-methyl-5-phenylpent-1-en-3-amine 
• 74-88-4 methyl iodide 
• 37904-38-4 5-phenylpent-1-en-3-ol 
• 1404462-22-1 C₁₇H₂₅NO₂ 
• 1404462-19-6 C₁₄H₁₉NO 
• 1404461-82-0 N-(4-methoxyphenyl)-N-methyl-[1-(2-phenylethyl)prop-2-en-1-yl]amine 
• 1246927-41-2 5-phenylpent-1-en-3-yl 2,2,2-trichloroacetimidate 

Downstream Products

• 1105971-79-6 (2S,4R)-4-(2-Aminoacetamido)-N-methyl-N-[(1R)-3-phenyl-1-(3-quinolylcarbamoyl)propyl]-2-pyrrolidinecarboxamide 

Relevant academic research and scientific papers

ENZYME INHIBITORS

The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2A, R2B, R3 and *1 are as defined herein.

Rhodium-catalyzed asymmetric amination of allylic trichloroacetimidates

A summary is presented of dynamic kinetic asymmetric transformations of racemic allylic trichloroacetimidates in the presence of chiral diene-ligated rhodium catalysts. The reaction is applicable to a wide variety of secondary and tertiary trichloroacetimidates containing aniline or benzylamine nucleophiles, affording nitrogen-containing tertiary and quaternary centers in good yields and with high levels of regio- and enantioselectivity. This catalytic method addresses many of the limitations previously associated with syntheses of these compounds. Georg Thieme Verlag Stuttgart - New York.

Rhodium-catalyzed regio- and enantioselective amination of racemic secondary allylic trichloroacetimidates with N-methyl anilines

We report the chiral diene ligated rhodium-catalyzed dynamic kinetic asymmetric transformation (DYKAT) of racemic secondary allylic trichloroacetimidates with a variety of N-methyl anilines, providing allylic N-methyl arylamines in high yields, regioselec

Rhodium-catalyzed regio- and enantioselective amination of racemic secondary allylic trichloroacetimidates with N-methyl anilines

We report the chiral diene ligated rhodium-catalyzed dynamic kinetic asymmetric transformation (DYKAT) of racemic secondary allylic trichloroacetimidates with a variety of N-methyl anilines, providing allylic N-methyl arylamines in high yields, regioselec

COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.

Compounds and Compositions as Channel Activating Protease Inhibitors

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.